secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001104659-22-099444
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gail Farfel named CEO of ProMIS Neurosciences effective Sept 19, 2022; Eugene Williams stays Chairman
--------------------------------------------------------------------------------

- Gail Farfel appointed CEO effective Sept 19, 2022; Eugene Williams steps down as CEO but remains Chairman.
- Dr. Farfel's base salary $500K (up to $535K after raising $75M), 50% bonus target, 208,334 stock options, $25K sign-on.
- Eugene Williams to receive $225K/yr as consultant for 3 years, plus severance on signing release.
- Dr. Farfel previously Chief Development Officer at Zogenix; led Fintepla Phase 3 and approvals for Dravet/LGS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/tm2225652d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-099444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer